Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteine and glycine-rich protein 3 (CSRP3), also referred to as cardiac LIM protein or muscle LIM protein, is a small structural protein (194 amino acids) encoded by the CSRP3 gene, predominantly expressed in cardiac and skeletal muscle. CSRP3 contains two LIM domains which mediate extensive protein–protein interactions with cytoskeletal, costameric, and nuclear factors, orchestrating sarcomeric organization, mechanical stretch sensing, and muscle differentiation. Mutations or altered expression of CSRP3 are directly linked to dilated and hypertrophic cardiomyopathy, as well as heart failure and various skeletal myopathies. CSRP3 serves as a scaffold essential for Z-disc integrity, actin filament stability, and mechanotransduction within myocytes, and also acts as a cofactor for transcription factors regulating myogenesis. Diagnostic and biomarker applications include detection of mutations or abnormal protein levels in cardiomyopathic tissues; however, direct pharmacological targeting and approved drugs for CSRP3 are currently absent
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3).